annual cash & cash equivalents:
$103.15M+$51.80M(+100.86%)Summary
- As of today (June 22, 2025), ADMA annual cash & cash equivalents is $103.15 million, with the most recent change of +$51.80 million (+100.86%) on December 31, 2024.
- During the last 3 years, ADMA annual cash & cash equivalents has risen by +$52.06 million (+101.90%).
- ADMA annual cash & cash equivalents is now at all-time high.
Performance
ADMA Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$71.63M-$31.52M(-30.56%)Summary
- As of today (June 22, 2025), ADMA quarterly cash & cash equivalents is $71.63 million, with the most recent change of -$31.52 million (-30.56%) on March 31, 2025.
- Over the past year, ADMA quarterly cash & cash equivalents has increased by +$26.30 million (+58.03%).
- ADMA quarterly cash & cash equivalents is now -30.56% below its all-time high of $103.15 million, reached on December 31, 2024.
Performance
ADMA quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ADMA Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +100.9% | +58.0% |
| 3 y3 years | +101.9% | +3.0% |
| 5 y5 years | +285.6% | -29.3% |
ADMA Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +101.9% | -30.6% | +105.2% |
| 5 y | 5-year | at high | +285.6% | -30.6% | +108.2% |
| alltime | all time | at high | >+9999.0% | -30.6% | >+9999.0% |
ADMA Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $71.63M(-30.6%) |
| Dec 2024 | $103.15M(+100.9%) | $103.15M(+19.0%) |
| Sep 2024 | - | $86.71M(-1.7%) |
| Jun 2024 | - | $88.24M(+94.7%) |
| Mar 2024 | - | $45.33M(-11.7%) |
| Dec 2023 | $51.35M(-40.6%) | $51.35M(-30.8%) |
| Sep 2023 | - | $74.16M(+18.6%) |
| Jun 2023 | - | $62.51M(-9.7%) |
| Mar 2023 | - | $69.20M(-20.0%) |
| Dec 2022 | $86.52M(+69.4%) | $86.52M(+147.9%) |
| Sep 2022 | - | $34.91M(-33.4%) |
| Jun 2022 | - | $52.42M(-24.6%) |
| Mar 2022 | - | $69.50M(+36.0%) |
| Dec 2021 | $51.09M(-8.6%) | $51.09M(+48.5%) |
| Sep 2021 | - | $34.41M(-18.9%) |
| Jun 2021 | - | $42.41M(-31.6%) |
| Mar 2021 | - | $61.97M(+10.8%) |
| Dec 2020 | $55.92M(+109.0%) | $55.92M(-6.3%) |
| Sep 2020 | - | $59.67M(-21.3%) |
| Jun 2020 | - | $75.78M(-25.1%) |
| Mar 2020 | - | $101.24M(+278.4%) |
| Dec 2019 | $26.75M(+17.6%) | $26.75M(-44.3%) |
| Sep 2019 | - | $48.01M(-34.8%) |
| Jun 2019 | - | $73.62M(+345.2%) |
| Mar 2019 | - | $16.53M(-27.3%) |
| Dec 2018 | $22.75M(-47.2%) | $22.75M(-46.3%) |
| Sep 2018 | - | $42.37M(-23.2%) |
| Jun 2018 | - | $55.15M(+111.2%) |
| Mar 2018 | - | $26.12M(-39.4%) |
| Dec 2017 | $43.11M | $43.11M(+216.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $13.60M(-46.8%) |
| Jun 2017 | - | $25.57M(+199.4%) |
| Mar 2017 | - | $8.54M(-13.8%) |
| Dec 2016 | $9.91M(-5.0%) | $9.91M(+25.4%) |
| Sep 2016 | - | $7.91M(-37.0%) |
| Jun 2016 | - | $12.55M(+40.6%) |
| Mar 2016 | - | $8.93M(-14.5%) |
| Dec 2015 | $10.44M(-39.3%) | $10.44M(+13.8%) |
| Sep 2015 | - | $9.18M(+17.3%) |
| Jun 2015 | - | $7.82M(-52.8%) |
| Mar 2015 | - | $16.56M(-3.7%) |
| Dec 2014 | $17.20M(-34.2%) | $17.20M(+23.3%) |
| Sep 2014 | - | $13.95M(-21.9%) |
| Jun 2014 | - | $17.87M(-32.6%) |
| Mar 2014 | - | $26.52M(+1.4%) |
| Dec 2013 | $26.15M(+108.6%) | $26.15M(+386.1%) |
| Sep 2013 | - | $5.38M(-29.7%) |
| Jun 2013 | - | $7.65M(-25.8%) |
| Mar 2013 | - | $10.32M(-17.7%) |
| Dec 2012 | $12.54M(>+9900.0%) | $12.54M(+16.9%) |
| Sep 2012 | - | $10.72M(-16.8%) |
| Jun 2012 | - | $12.89M(-9.5%) |
| Mar 2012 | - | $14.24M(>+9900.0%) |
| Dec 2011 | - | $8100.00(+37.3%) |
| Sep 2011 | - | $5900.00(-30.6%) |
| Jun 2011 | $8500.00(-29.2%) | $8500.00(-47.5%) |
| Mar 2011 | - | $16.20K(+422.6%) |
| Dec 2010 | - | $3100.00(-74.2%) |
| Jun 2010 | - | $12.00K |
| Jun 2010 | $12.00K | - |
FAQ
- What is ADMA Biologics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ADMA Biologics?
- What is ADMA Biologics annual cash & cash equivalents year-on-year change?
- What is ADMA Biologics quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for ADMA Biologics?
- What is ADMA Biologics quarterly cash & cash equivalents year-on-year change?
What is ADMA Biologics annual cash & cash equivalents?
The current annual cash & cash equivalents of ADMA is $103.15M
What is the all time high annual cash & cash equivalents for ADMA Biologics?
ADMA Biologics all-time high annual cash & cash equivalents is $103.15M
What is ADMA Biologics annual cash & cash equivalents year-on-year change?
Over the past year, ADMA annual cash & cash equivalents has changed by +$51.80M (+100.86%)
What is ADMA Biologics quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of ADMA is $71.63M
What is the all time high quarterly cash & cash equivalents for ADMA Biologics?
ADMA Biologics all-time high quarterly cash & cash equivalents is $103.15M
What is ADMA Biologics quarterly cash & cash equivalents year-on-year change?
Over the past year, ADMA quarterly cash & cash equivalents has changed by +$26.30M (+58.03%)